The function of Core B is to provide human and immune cell phenotyping for each project that will be critical to the translation of mechanistic findings into the human model. The effects of immune cell variations on atherosclerosis in humans represents a poody understood area of atherogenesis and possible atheroprotection. The goal of the Human Phenotyping and Immune Cell Core (Core B) is to provide the resources necessary for translation of novel immune mechanisms of atherosclerosis that are well defined in murine models into the human model. Specifically, we will provide well-defined phenotypes of atherosclerosis burden and risk in patients with and without type 2 diabetes, genotyping analysis, and phenotypic descriptions of immune cells in humans using flow cytometry. Core B will work with each of the three projects to provide in patients, with and without Type 2 diabetes, well-defined phenotypes of atherosclerosis burden and risk using the Framingham risk Score and carotid intima-media thickness (projects 1-3);serum and plasma measurement of traditional atherosclerotic risk factors (projects 1-3);genotyping of single nucleotide polymorphisms related to atherosclerotic mechanisms (project 3);isolation and FACS analysis of immune cells (projects 1,3);and collection and shipping of serum and plasma for analysis by individual projects (projects 1-3).

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL055798-16A1
Application #
8396707
Study Section
Special Emphasis Panel (ZHL1-CSR-A (M1))
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
16
Fiscal Year
2012
Total Cost
$375,435
Indirect Cost
$18,500
Name
La Jolla Institute
Department
Type
DUNS #
603880287
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Verbeek, Rutger; Boekholdt, S Matthijs; Stoekenbroek, Robert M et al. (2016) Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. J Lipid Res 57:697-705
Yang, Xiaohong; Lee, Sang-Rok; Choi, Yun-Seok et al. (2016) Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res 57:706-13
Harmon, Daniel B; Srikakulapu, Prasad; Kaplan, Jennifer L et al. (2016) Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance. Arterioscler Thromb Vasc Biol 36:682-91
Choi, Soo-Ho; Kim, Jungsu; Gonen, Ayelet et al. (2016) MD-2 binds cholesterol. Biochem Biophys Res Commun 470:877-80
Park, Kiwon; Mikulski, Zbigniew; Seo, Goo-Young et al. (2016) The transcription factor NR4A3 controls CD103+ dendritic cell migration. J Clin Invest 126:4603-4615
Choi, Soo-Ho; Sviridov, Dmitri; Miller, Yury I (2016) Oxidized cholesteryl esters and inflammation. Biochim Biophys Acta :
Yeang, Calvin; Cotter, Bruno; Tsimikas, Sotirios (2016) Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis. Cardiovasc Drugs Ther 30:75-85
Tsimikas, Sotirios (2016) Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes 23:157-64
Leibundgut, Gregor; Lee, Jun-Hee; Strauss, Bradley H et al. (2016) Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina. J Thromb Thrombolysis 41:569-80
Cheng, Hsin-Yuan; Gaddis, Dalia E; Wu, Runpei et al. (2016) Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis. J Clin Invest 126:3236-46

Showing the most recent 10 out of 188 publications